European Commission logo
polski polski
CORDIS - Wyniki badań wspieranych przez UE

Cutting edge microwave imaging device for safe and accurate breast cancer screening

Periodic Reporting for period 3 - MammoWave (Cutting edge microwave imaging device for safe and accurate breast cancer screening)

Okres sprawozdawczy: 2021-04-01 do 2021-08-31

The MammoWave project addresses the shortcomings and risks associated with mammography. Mammography has been the medical industry’s “gold standard” breast cancer screening tool for nearly four decades. However, a number of adverse effects, including those caused by exposure to x-rays, are now limiting the use of mammography as a mass screening.

Finding a reliable and safer alternative to mammography is key to reduce the burden of breast cancer to society. Breast cancer is the most prevalent form of cancer in women. One in nine women will acquire breast cancer at some point in their life and one in thirty will die from the disease.

The overall objectives of the MammoWave H2020 project are:

1) Development of a interoperable application for MammoWave imaging management
2) Prove MammoWave large scale manufacturability and assembly repeatability
3) Validate MammoWave’s performances in international clinical study
4) Develop international commercial channels
Throughout the entire, UBT has been working on all the five work packages, with significant results secured:

1) Development and delivery of the suite of software managing the operations of the MammoWave device (WP1)
2) Conversion of the MammoWave’s output into DICOM format for the complete interoperability of the device in every hospital environment (Milestone of this project, WP1)
3) Assembly and successful testing of the first batch of 8 MammoWave units (MammoWave IV generation) (WP2)
4) Ethics committee authorisation from hospitals San Martino (Genova, Italy), Humanitas (Milan, Italy), Hospital Virgen de la Salud (Toledo, Spain) (WP3)
5) Clinical validation performed on 354 patients in 3 clinics, showing positive results of Mammowave (WP3)
6) Publications on prestigious journals such as Scientific Reports (a natureresearch journal) and Biomedical Signal Processing and Control (Elsevier)(WP4)
7) Identification of strong potential commercial partners and significant progress with selected investors (WP4)
The international clinical study confirmed MammoWave's overall accuracy above 80%. The clinical study was conducted on 354 patients, way above the 250 limit needed to collect statistical significant data for obtaining fast market approval. These results are expected to fast track MammoWave's entry into the EU market. Therefore, the MammoWave H2020 project can have a big impact on the company boosting UBT's growth and commercial success. And, most importantly, on the millions of patients looking for a safer and reliable breast cancer screening alternative.
The team standing behind the newly assembled MammoWave